KR102764357B1 - 생체내 수용체 점유율을 결정하기 위한 검정 - Google Patents

생체내 수용체 점유율을 결정하기 위한 검정 Download PDF

Info

Publication number
KR102764357B1
KR102764357B1 KR1020207035120A KR20207035120A KR102764357B1 KR 102764357 B1 KR102764357 B1 KR 102764357B1 KR 1020207035120 A KR1020207035120 A KR 1020207035120A KR 20207035120 A KR20207035120 A KR 20207035120A KR 102764357 B1 KR102764357 B1 KR 102764357B1
Authority
KR
South Korea
Prior art keywords
drug
bound
btk
leu
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207035120A
Other languages
English (en)
Korean (ko)
Other versions
KR20210008028A (ko
Inventor
나이유 젱
이안 맥쿼리 캐틀렛
지아닝 젱
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020257003448A priority Critical patent/KR20250021652A/ko
Publication of KR20210008028A publication Critical patent/KR20210008028A/ko
Application granted granted Critical
Publication of KR102764357B1 publication Critical patent/KR102764357B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
KR1020207035120A 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정 Active KR102764357B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257003448A KR20250021652A (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669442P 2018-05-10 2018-05-10
US62/669,442 2018-05-10
PCT/US2019/031524 WO2019217684A1 (en) 2018-05-10 2019-05-09 Assay to determine in vivo receptor occupancy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257003448A Division KR20250021652A (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Publications (2)

Publication Number Publication Date
KR20210008028A KR20210008028A (ko) 2021-01-20
KR102764357B1 true KR102764357B1 (ko) 2025-02-10

Family

ID=66821369

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207035120A Active KR102764357B1 (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정
KR1020257003448A Pending KR20250021652A (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257003448A Pending KR20250021652A (ko) 2018-05-10 2019-05-09 생체내 수용체 점유율을 결정하기 위한 검정

Country Status (7)

Country Link
US (2) US12085564B2 (enExample)
EP (1) EP3791183B1 (enExample)
JP (2) JP7570925B2 (enExample)
KR (2) KR102764357B1 (enExample)
CN (2) CN113804873B (enExample)
ES (1) ES2992942T3 (enExample)
WO (1) WO2019217684A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992942T3 (en) 2018-05-10 2024-12-20 Bristol Myers Squibb Co Assay to determine in vivo receptor occupancy
CN115932261B (zh) * 2022-08-15 2025-07-25 广州医科大学附属第五医院 一种btk受体占有率的检测方法
CN116482345B (zh) * 2023-06-16 2023-09-22 军科正源（北京）药物研究有限责任公司 用于检测双靶点药物受体占有率的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010240A1 (en) * 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
US20160252509A1 (en) * 2013-08-13 2016-09-01 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062255A1 (en) * 2007-08-17 2009-03-05 Thallion Pharmaceuticals Inc. Tumor-targeting evaluation methodology and compounds related thereto
WO2016100593A1 (en) * 2014-12-17 2016-06-23 Pharmacyclics Llc Methods and assays for quantification and normalization of kinase and ligand binding
ES2992942T3 (en) 2018-05-10 2024-12-20 Bristol Myers Squibb Co Assay to determine in vivo receptor occupancy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010240A1 (en) * 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
US20160252509A1 (en) * 2013-08-13 2016-09-01 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cynthia D. Jesudason et al., In Vivo Receptor Occupancy in Rodents by LC-MS/MS, 2017, Assay Guidance Manual. 1부.*

Also Published As

Publication number Publication date
CN112105930B (zh) 2025-02-28
CN113804873B (zh) 2024-06-18
US12085564B2 (en) 2024-09-10
KR20210008028A (ko) 2021-01-20
ES2992942T3 (en) 2024-12-20
JP2025011208A (ja) 2025-01-23
JP7570925B2 (ja) 2024-10-22
EP3791183A1 (en) 2021-03-17
CN113804873A (zh) 2021-12-17
WO2019217684A1 (en) 2019-11-14
KR20250021652A (ko) 2025-02-13
EP3791183B1 (en) 2024-07-24
JP2021523367A (ja) 2021-09-02
CN112105930A (zh) 2020-12-18
US20250085279A1 (en) 2025-03-13
US20210156854A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
US20250085279A1 (en) Assay to determine in vivo receptor occupancy
Kulyyassov et al. Targeted liquid chromatography‐tandem mass spectrometry analysis of proteins: basic principles, applications, and perspectives
Cox et al. Multiple reaction monitoring as a method for identifying protein posttranslational modifications
Percy et al. Comparison of standard-and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins
Whiteaker et al. Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry
Li et al. Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing
Faria et al. Comparison of a stable isotope labeled (SIL) peptide and an extended SIL peptide as internal standards to track digestion variability of an unstable signature peptide during quantification of a cancer biomarker, human osteopontin, from plasma using capillary microflow LC–MS/MS
Beasley-Green Urine proteomics in the era of mass spectrometry
Wu et al. A strategy for liquid chromatography/tandem mass spectrometry based quantitation of pegylated protein drugs in plasma using plasma protein precipitation with water‐miscible organic solvents and subsequent trypsin digestion to generate surrogate peptides for detection
CA2732109A1 (en) Mass spectrometry assay for plasma-renin
Ji et al. A universal strategy for development of a method for absolute quantification of therapeutic monoclonal antibodies in biological matrices using differential dimethyl labeling coupled with ultra performance liquid chromatography-tandem mass spectrometry
Fert‐Bober et al. Proteomics of citrullination in cardiovascular disease
Kim et al. Quantitative analysis of low-abundance serological proteins with peptide affinity-based enrichment and pseudo-multiple reaction monitoring by hybrid quadrupole time-of-flight mass spectrometry
Li et al. Peptide and protein quantification using automated immuno-MALDI (iMALDI)
Huang et al. Identification and quantification of immunoglobulin G (G1, G2, G3 and G4) in human blood plasma by high-resolution quadrupole-Orbitrap mass spectrometry
Zhi et al. Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification
Chen et al. Sequential immunoaffinity-LC/MS assay for quantitation of a therapeutic protein in monkey plasma
Kuhn et al. Multiplexed immunoaffinity enrichment of peptides with anti-peptide antibodies and quantification by stable isotope dilution multiple reaction monitoring mass spectrometry
JP7629278B2 (ja) Ａβペプチドを測定するための抗体セット、Ａβペプチドの測定方法及び試薬キット
Gould et al. LC-MS/MS method for quantifying the HIV-1 broadly neutralizing antibody PGT 121.414. LS in human serum
Grote et al. Using pure protein to build a multiple reaction monitoring mass spectrometry assay for targeted detection and quantitation
Tao et al. High-throughput protein modification quantitation analysis using intact protein MRM and its application on hENGase inhibitor screening
Geumann et al. A sandwich enzyme-linked immunosorbent assay for the quantification of insoluble membrane and scaffold proteins
Park et al. Qualification and application of a liquid chromatography–quadrupole time‐of‐flight mass spectrometric method for the determination of trastuzumab in rat plasma
Dahabiyeh et al. Measurement of the total angiotensinogen and its reduced and oxidised forms in human plasma using targeted LC-MS/MS

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220426

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240222

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241101

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250203

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration